Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk receives EU approval for use of Novorapid in elderly

Novo Nordisk receives EU approval for use of Novorapid in elderly

20th September 2007

Novo Nordisk announced today that the European commission has approved Novorapid (insulin aspart) for treatment of diabetes in elderly people and those with renal or hepatic impairment.

The rapid-acting insulin has been available since 1999 but with the approval it is now safe to use by all people from two years of age with types one or two diabetes.

Dr Tim Heise, CEO of clinical science, recounted how trials conducted in 2001 and 2002 showed that Novorapid was absorbed rapidly and reached peak activity in a short-time for the elderly population, thus allowing flexible treatment with improved meal-time coverage.

He went on to indicate: “The new approval of insulin aspart provides a new treatment option for those patients who have difficulties in maintaining acceptable blood glucose levels around mealtimes with their current human insulin treatment.?

Dr Heise marked the importance of the commission’s approval, explaining that diabetes was a progressive disease meaning older people often required more intensive insulin therapy as time goes on.

Earlier this week, Novo Nordisk announced the results of the fourth of its five phase III clinical trials showing liraglutide to have strong efficacy data when measuring the effect and action of the compound in diabetes patients.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.